2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors
Patnaik A, LoRusso P, Munster P, Tolcher A, Davis S, Heymach J, Ferraroto R, Xu L, Kapoun A, Faoro L, Lewicki J, Dupont J, Eckhardt S. 2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors. European Journal Of Cancer 2014, 50: 7. DOI: 10.1016/s0959-8049(14)70128-5.Peer-Reviewed Original Research